Abstract:G protein coupled receptors (GPCRs) were first characterized as signal transducers that elicit downstream effects through modulation of guanine (G) nucleotide-binding proteins. The pharmacotherapeutic exploitation of this signaling paradigm has created a drug-based field covering nearly 50% of the current pharmacopeia. Since the groundbreaking discoveries of the late 1990s to the present day, it is now clear however that GPCRs can also generate productive signaling cascades through the modulation of β-arrestin functionality. β-Arrestins were first thought to only regulate receptor desensitization and internalization - exemplified by the action of visual arrestin with respect to rhodopsin desensitization. Nearly 20 years ago, it was found that rather than controlling GPCR signal termination, productive β-arrestin dependent GPCR signaling paradigms were highly dependent on multi-protein complex formation and generated long-lasting cellular effects, in contrast to G protein signaling which is transient and functions through soluble second messenger systems. β-Arrestin signaling was then first shown to activate mitogen activated protein kinase signaling in a G protein-independent manner and eventually initiate protein transcription - thus controlling expression patterns of downstream proteins. While the possibility of developing β-arrestin biased or functionally selective ligands is now being investigated, no additional research has been performed on its possible contextual specificity in treating age-related disorders. The ability of β-arrestin-dependent signaling to control complex and multidimensional protein expression patterns makes this therapeutic strategy feasible, as treating complex age-related disorders will likely require therapeutics that can exert network-level efficacy profiles. It is our understanding that therapeutically targeting G protein-independent effectors such as β-arrestin will aid in the development of precision medicines with tailored efficacy profiles for disease/age-specific contextualities.

Β-Arrestins As Potential Therapeutic Targets for Alzheimer’s Disease

The multifaceted functions of β-arrestins and their therapeutic potential in neurodegenerative diseases

Arrestins contribute to amyloid beta-induced cell death via modulation of autophagy and the α7nAch receptor in SH-SY5Y cells

Roles of Beta-Adrenergic Receptors in Alzheimer'S Disease: Implications for Novel Therapeutics

Astrocytic AT1R deficiency ameliorates Aβ-induced cognitive deficits and synaptotoxicity through β-arrestin2 signaling

-arrestin1 promotes tauopathy by transducing GPCR signaling, disrupting microtubules and autophagy

Therapeutic Potential of Targeting ß-Arrestin

The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease

Insight into the regulatory mechanism of β-arrestin2 and its emerging role in diseases

Involvement of Β-Arrestins in Cancer Progression

β-Arrestin Based Receptor Signaling Paradigms: Potential Therapeutic Targets for Complex Age-Related Disorders

Β-Arrestins: Multifunctional Signaling Adaptors in Type 2 Diabetes.

A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment

Potential Therapeutic Strategies for Alzheimer's Disease Targeting or Beyond Β-Amyloid: Insights from Clinical Trials

The role and mechanism of β-arrestin2 in signal transduction

Classical and new roles of β-arrestins in the regulation of G-PROTEIN-COUPLED receptors

Functional Specialization of Β-Arrestin Interactions Revealed by Proteomic Analysis

Potential Therapeutic Strategies for Alzheimer’s Disease Targeting or Beyondβ-Amyloid: Insights from Clinical Trials

Regulation of Α2a Adrenergic Receptor Trafficking and Signaling by Amyloid Precursor Protein

β-arrestin2: an emerging player and potential therapeutic target in inflammatory immune diseases

Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease